SARS-CoV-2 Infection and Vaccination, Immune Dysregulation, and Cancer

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• SARS-CoV-2 infection triggers varied immune responses impacting disease severity and long-term immune changes.
• A critical question is whether SARS-CoV-2 directly causes cancer or temporarily enhances tumor-permissive pathways.

Purpose of the Study:

• To investigate the oncogenic potential of SARS-CoV-2 infection and the impact of vaccination on cancer-related pathways.

Main Methods:

• Analysis of molecular mechanisms, including viral protein interactions with host signaling pathways (e.g., spike protein with TLR2/TLR4-MyD88, membrane protein with NF-κB-STAT3).
• Evaluation of immune responses, cytokine signaling (IL-6/JAK-STAT3, MAPK), metabolic reprogramming, and immune evasion mechanisms.
• Comparison of immune responses induced by infection versus vaccination.

Main Results:

• Severe SARS-CoV-2 infection does not support classical viral oncogenesis but amplifies pre-existing oncogenic signaling via inflammatory pathways.
• Viral proteins modulate host signaling, intensifying inflammation and impairing antitumor immunity.
• Vaccination induces limited, transient immune activation without sustained inflammation or evidence of increased cancer incidence.

Conclusions:

• SARS-CoV-2 infection temporarily reinforces tumor-permissive pathways but does not initiate cancer.
• Vaccination mitigates severe disease and associated immune dysregulation, interrupting pathways potentially linked to cancer.
• Long-term studies are needed to fully understand the oncologic implications of post-infectious immune remodeling.